CL2017001611A1 - Un proceso para la producción de complejos de caseína n-acetil-aspartilada de hierro (iii) y uso del mismo en composiciones farmacéuticas - Google Patents

Un proceso para la producción de complejos de caseína n-acetil-aspartilada de hierro (iii) y uso del mismo en composiciones farmacéuticas

Info

Publication number
CL2017001611A1
CL2017001611A1 CL2017001611A CL2017001611A CL2017001611A1 CL 2017001611 A1 CL2017001611 A1 CL 2017001611A1 CL 2017001611 A CL2017001611 A CL 2017001611A CL 2017001611 A CL2017001611 A CL 2017001611A CL 2017001611 A1 CL2017001611 A1 CL 2017001611A1
Authority
CL
Chile
Prior art keywords
iron
iii
acetii
caseine
aspartylated
Prior art date
Application number
CL2017001611A
Other languages
English (en)
Inventor
Ioulia Tseti
Original Assignee
Ioulia Tseti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ioulia Tseti filed Critical Ioulia Tseti
Publication of CL2017001611A1 publication Critical patent/CL2017001611A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732Casein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE EN GENERAL A UN NUEVO PROCESO PARA LA PREPARACIÓN DE COMPLEJOS DE CASEÍNA N-ACETIL-ASPARTILADA DE HIERRO (III). EL PRODUCTO OBTENIBLE DE ACUERDO CON EL MÉTODO DE LA PRESENTE INVENCIÓN PUEDE SER USADO DE MODO SEGURO PARA LA POBLACIÓN EN GENERAL O LOS ANIMALES EN EL TRATAMIENTO DE LA DEFICIENCIA DE HIERRO. EL PROCESO DE LA INVENCIÓN INCLUYE LAS ETAPAS DE: (A) UNA REACCIÓN DE LA CASEÍNA CON CLORURO DE N-ACETII-L-ASPARTI LO, PARA FORMAR CASEÍNA N-ACETII-L-ASPARTILADA, (B) UNA REACCIÓN POSTERIOR DE LA CASEÍNA N-ACETII-L-ASPARTILADA CON CLORURO FÉRRICO; Y (E) OBTENER EL COMPLEJO DE HIERRO (111) CON CASEÍNA N-ACETII-L-ASPARTILADA.</p>
CL2017001611A 2014-12-19 2017-06-19 Un proceso para la producción de complejos de caseína n-acetil-aspartilada de hierro (iii) y uso del mismo en composiciones farmacéuticas CL2017001611A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14386034.4A EP3034512B1 (en) 2014-12-19 2014-12-19 A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CL2017001611A1 true CL2017001611A1 (es) 2018-01-26

Family

ID=52354737

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001611A CL2017001611A1 (es) 2014-12-19 2017-06-19 Un proceso para la producción de complejos de caseína n-acetil-aspartilada de hierro (iii) y uso del mismo en composiciones farmacéuticas

Country Status (29)

Country Link
US (1) US20170340747A1 (es)
EP (1) EP3034512B1 (es)
AP (1) AP2017009801A0 (es)
AU (1) AU2015365885B2 (es)
BR (1) BR112017006621B1 (es)
CA (1) CA2959226C (es)
CL (1) CL2017001611A1 (es)
CO (1) CO2017003313A2 (es)
CY (1) CY1120037T1 (es)
DK (1) DK3034512T3 (es)
EA (1) EA031968B1 (es)
ES (1) ES2655238T3 (es)
GE (1) GEP20207081B (es)
HR (1) HRP20171965T1 (es)
HU (1) HUE035302T2 (es)
IL (1) IL251449B (es)
LT (1) LT3034512T (es)
MX (1) MX2017008100A (es)
MY (1) MY185391A (es)
NO (1) NO3034512T3 (es)
PE (1) PE20180660A1 (es)
PH (1) PH12017500391A1 (es)
PL (1) PL3034512T3 (es)
PT (1) PT3034512T (es)
RS (1) RS56714B1 (es)
SA (1) SA517381261B1 (es)
SG (1) SG11201702593TA (es)
SI (1) SI3034512T1 (es)
WO (1) WO2016096203A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1009589B (el) 2018-04-05 2019-09-11 Ιουλια Κλεωνος Τσετη Φαρμακευτικο σκευασμα για την αντιμετωπιση της αναιμιας, σε καταλληλο περιεκτη, που διατηρει στεγανα διαχωρισμενα μεταξυ τους τα δραστικα συστατικα: συμπλοκο του τρισθενους σιδηρου με ν-ακετυλο-l-ασπαρτικη καζεϊνη και πενταϋδρικο φυλλινικο ασβεστιο

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB910321A (en) 1960-02-25 1962-11-14 Olivier Paul Gaudin Improvements in and relating to a process for preparing ferrous salts of aspartic acid and medicines containing these salts
IT1150213B (it) 1982-03-02 1986-12-10 Italfarmaco Spa Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche
IT1207996B (it) 1986-03-18 1989-06-01 Magis Farmaceutici Composti contenenti ferro biodisponibile, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
GB9621273D0 (en) 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
IT1297022B1 (it) 1997-12-24 1999-08-03 Chemi Spa Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono
ITMO20040200A1 (it) 2004-07-29 2004-10-29 Biofer Spa Processo per la produzione di complessi ferro succinilcaseina e ferro casein acetil aspartilato e loro utilizzato nelle relative composizioni farmaceutiche.

Also Published As

Publication number Publication date
CA2959226A1 (en) 2016-06-23
NO3034512T3 (es) 2018-05-05
BR112017006621A2 (pt) 2017-12-19
LT3034512T (lt) 2018-01-25
SI3034512T1 (en) 2018-04-30
PH12017500391B1 (en) 2017-07-17
HRP20171965T1 (hr) 2018-02-23
RS56714B1 (sr) 2018-03-30
AP2017009801A0 (en) 2017-03-31
SG11201702593TA (en) 2017-04-27
WO2016096203A1 (en) 2016-06-23
IL251449A0 (en) 2017-05-29
EP3034512A1 (en) 2016-06-22
US20170340747A1 (en) 2017-11-30
AU2015365885B2 (en) 2018-11-15
CY1120037T1 (el) 2018-12-12
DK3034512T3 (en) 2018-01-15
HUE035302T2 (en) 2018-05-02
MX2017008100A (es) 2017-10-31
PT3034512T (pt) 2018-01-11
CO2017003313A2 (es) 2017-07-28
ES2655238T3 (es) 2018-02-19
GEP20207081B (en) 2020-03-25
MY185391A (en) 2021-05-17
PE20180660A1 (es) 2018-04-17
SA517381261B1 (ar) 2017-12-20
EP3034512B1 (en) 2017-12-06
EA201790902A1 (ru) 2017-10-31
IL251449B (en) 2019-02-28
PH12017500391A1 (en) 2017-07-17
BR112017006621B1 (pt) 2023-11-07
AU2015365885A1 (en) 2017-03-16
PL3034512T3 (pl) 2018-03-30
EA031968B1 (ru) 2019-03-29
CA2959226C (en) 2018-10-09

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MD4733B1 (ro) Anticorpi anti-TIGIT
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
MX2015010125A (es) Derivados de piridazinona-amidas.
CL2015002387A1 (es) Nuevos derivados de pirazol.
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
EA201791182A1 (ru) Новые производные 2&#39;- и/или 5&#39;-аминокислотных эфиров фосфороамидатов 3&#39;-дезоксиаденозина в качестве противораковых соединений
MX2017003621A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso.
MX2019015888A (es) Bifenil amidas con grupos eter modificados como inhibidores de hsp90 e inductores de hsp70.
MX2017003365A (es) Tinturas dispersas altamente resistentes a la humedad y sus mezclas.
MX2018008644A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
TW201613953A (en) Process for the preparation of cyclic depsipeptides
CR20190131A (es) 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
EA201691871A1 (ru) Растворы силденафила и способы их получения и применения
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
CL2017001611A1 (es) Un proceso para la producción de complejos de caseína n-acetil-aspartilada de hierro (iii) y uso del mismo en composiciones farmacéuticas
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CR20150545A (es) Agentes quelantes de precursores de producto final de glicación avanzada (age)
EA202090728A1 (ru) Применение нор-урсодезоксихолевой кислоты для снижения печеночного жира
MX2016005222A (es) Tinturas acidas, proceso para su produccion y su uso.
CL2015002790A1 (es) Proceso para utilizar una formulación floculante como único producto para la precipitación y recuperación de riles provenientes de la descarga, bombeo y/o procesamiento de peces u otros recursos animales; formulación floculante